Pages that link to "Q39210153"

The following pages link to Biochemical and pharmacological characterization of AZD1981, an orally available selective DP2 antagonist in clinical development for asthma (Q39210153):

Displaying 9 items.

• Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs (Q28299410) (← links)
• Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy. (Q34515787) (← links)
• Investigational prostaglandin D2 receptor antagonists for airway inflammation (Q38812321) (← links)
• CRTH2 antagonists in asthma: current perspectives (Q47119852) (← links)
• Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β2-agonists in patients with atopic asthma. (Q53681659) (← links)
• Comparison of Effect of Leukotriene Biosynthesis Blockers and Inhibitors of Phosphodiesterase Enzyme in Patients with Bronchial Hyperreactivity. (Q55016315) (← links)
• Exploring the insulin secretory properties of the PGD2-GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patients (Q60301725) (← links)
• Inhibition of CRTH2-mediated Th2 activation attenuates pulmonary hypertension in mice (Q64137186) (← links)
• Effects of an Oral CRTh2 Antagonist (AZD1981) on Eosinophil Activity and Symptoms in Chronic Spontaneous Urticaria (Q92414706) (← links)